<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671435</url>
  </required_header>
  <id_info>
    <org_study_id>D419NC00001</org_study_id>
    <secondary_id>D419NC00001</secondary_id>
    <nct_id>NCT02671435</nct_id>
  </id_info>
  <brief_title>A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects With Select Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study
      to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and
      immunogenicity of Durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in Adult
      Subjects with selected advanced solid tumors and the combination of durvalumab and
      monalizumab (IPH2201) standard of care systemic therapy with or without biological agent
      administered to subjects with recurrent or metastatic colorectal cancer (CRC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 3 parts: dose escalation (Part 1), dose expansion (Part 2), and dose
      exploration (Part 3). Part 1 will evaluate dose escalation of durvalumab in combination with
      monalizumab in adult subjects with select advanced solid tumor malignancies. Part 2 will
      evaluate further the identified dose of durvalumab in combination with monalizumab from Part
      1 in adult subjects with select advanced solid tumor malignancies. Part 3 will evaluate dose
      exploration of durvalumab in combination with monalizumab standard of care systemic therapy
      with or without biological agent in adult subjects with CRC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Anticipated">January 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Drug Limited Toxicities (DLTs)</measure>
    <time_frame>From Time of First dose through DLT Screening period</time_frame>
    <description>To assess by the occurrence of Drug Limited Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in vital signs from baseline</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess safety of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess by the occurrence of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in electrocariogram (ECG) from baseline</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess safety of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess by the occurrence of serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in laboratory parameters from baseline</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess safety of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers predicting expression of PD-L1 and HLA-E.</measure>
    <time_frame>From time of screening through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess biomarker predicting activity of IPH2201+durva in combo with standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop anti-drug antibodies</measure>
    <time_frame>From time of first dose through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess the immunogenicity of mona+durva with or without standard of care systemic therapy or biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durva and monalizumab serum peak concentration (cMax) concentration for Pharmacokinetics</measure>
    <time_frame>From time of first dose through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess the pharmacokinetics of Durvalumab and IPH2201 or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durva and monalizumab serum area under the concentration-time curve (AUC) concentration for Pharmacokinetics</measure>
    <time_frame>From time of first dose through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess the pharmacokinetics of Durvalumab and IPH2201 or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durva and monalizumab serum clearance (CL) concentration for Pharmacokinetics</measure>
    <time_frame>From time of first dose through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess the pharmacokinetics of Durvalumab and IPH2201 or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durva and monalizumab serum terminal elimination half-life (t1/2) concentration for Pharmacokinetics</measure>
    <time_frame>From first dose through 90 days (+/- 7 days) after the last dose of study medication</time_frame>
    <description>To assess the pharmacokinetics of Durvalumab and IPH2201 or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From time of first dose of study medication through 5 years</time_frame>
    <description>To assess anti-tumor activity of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From time of first dose of study medication through 5 years</time_frame>
    <description>To assess anti-tumor activity of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From time of first dose of study medication through 5 years</time_frame>
    <description>To assess anti-tumor activity of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From time of first dose of study medication through 5 years</time_frame>
    <description>To assess anti-tumor activity of IPH2201 +durva, or IPH2201+durva +standard of care systemic therapy with or without biological agent</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1 -Dose escalation with 5 dose escalation cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab and IPH2201</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Dose expansion with 4 dose expansion cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab and IPH2201</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 -Dose Exploration with 6 dose exploration cohorts.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab and IPH2201 and standard of standard of care systemic therapy in CRC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Biological: Durvalumab Biological: Monalizumab (IPH2201)</description>
    <arm_group_label>Part 1 -Dose escalation with 5 dose escalation cohorts</arm_group_label>
    <arm_group_label>Part 2 - Dose expansion with 4 dose expansion cohorts</arm_group_label>
    <arm_group_label>Part 3 -Dose Exploration with 6 dose exploration cohorts.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have histologic documentation of advanced recurrent or metastatic
             cancer.

          2. Subjects must be at the recurrent/metastatic setting, with selected advanced solid
             tumors.

          3. Subjects must have at least one lesion that is measurable by RECIST v1.1

          4. Part 3, Dose exploration, CRC subjects can be treatment naïve but should not have
             received more than one line of systemic therapy in the recurrent/metastatic setting.

        Exclusion Criteria

          1. Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may
             be permitted upon discussion with the medical monitor.

          2. Prior participation in clinical studies that include durvalumab alone or in
             combination, where the study has registrational intent and the analyses for the
             primary endpoint have not yet been completed

          3. Receipt of any conventional or investigational anticancer therapy within 4 weeks prior
             to the first dose of durvalumab and IPH2201

          4. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
             treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille CEDEX 5</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes CEDEX 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SW2 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer, colon cancer, CRC, solid tumors, check point inhibitors, immunotherapy, chemotherapy, metastatic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

